requiring dialysis, colonic ischemia requiring resection, limb ischemia requiring amputation, multisystem organ failure, or death. Endoleaks were classified in accordance with the standardized reporting practices of the Society for Vascular Surgery. Results: A total of 391 patients with complete family history and clinical data underwent elective AAA repair from 2004 to 2014. Demographics were consistent with a standard AAA population and did not differ between fAAA and spAAA patients. Sixty-two percent (n ¼ 56) of fAAA patients and 68% (n ¼ 203) of spAAA patients underwent EVAR (P ¼ .31). The fAAA patients did not incur any greater risk of major adverse events after EVAR (fAAA: 11% vs spAAA: 9%; P ¼ .8) or open AAA repair (fAAA: 11% vs spAAA: 15%; P ¼ .78). Despite no difference in major morbidity, the fAAA patients did have an increased rate of all types of endoleak (fAAA: 23% vs spAAA: 12%; P ¼ .05). Furthermore, the rate of type I endoleak and subsequent reintervention for type I endoleak did differ between the groups (fAAA: 7% vs spAAA: 1%; P ¼ .02). In contrast, reintervention for all types of endoleak after EVAR (fAAA: 13% vs spAAA: 8%; P ¼ .16) did not differ between fAAA and spAAA patients. Conclusions: The current study demonstrates that patients with fAAA do not have increased morbidity after AAA repair but are more prone to endoleak after EVAR. We believe our results, combined with those of others, suggest EVAR for fAAA is safe and effective but fAAA patients represent a subpopulation that would benefit from close postprocedural surveillance.

Key Clinical MessageRifaximin has only been rarely reported to cause rhabdomyolysis. When physical and nonphysical etiologies have been excluded, thorough review of the patient’s medication list is necessary. In cirrhotics, the potential harm of rifaximin in treatment or prophylaxis of hepatic encephalopathy should be recognized.